---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211973"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:57:34.003078+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences Q1 net loss $40.4M, cash $311.3M; pipeline and CMO appointment

## Summary
- Net loss $40.4M for Q1 2026 vs $38.2M in Q1 2025, driven by higher R&D and G&A costs.
- Cash, equivalents, and investments $311.3M at March 31, 2026; funding expected into first half 2028.
- JADE101 Phase 1 interim biomarker data to be presented at ERA Congress; Phase 2 in IgAN expected Q2 2026.
- JADE201 Phase 1 trial in rheumatoid arthritis expected to start Q2 2026; interim data in 2027.
- Appointed Edward R. Conner, M.D., as CMO; promoted Andrew King to President, R&D.

## SEC filing metadata
- accession: 0001193125-26-211973
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312526211973/0001193125-26-211973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312526211973/d108669d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211973
- JSON: https://secwatch.observer/filing/0001193125-26-211973.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211973.txt

## Source-grounded claims
- claim_id: 24a8816e63ea26fdb74c6ee23f76f3b7a26a228e
  claim: Jade Biosciences, Inc. reported the quarter ended March 31, 2026 results: net income Net loss totaled $40.4 million for the first quarter ended March 31, 2026.
  evidence_excerpt: On May 7, 2026, Jade Biosciences, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000119312526211973/0001193125-26-211973-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.